Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …

Non-alcoholic fatty liver disease (NAFLD) is to date the most common chronic liver disease
in clinical practice and, consequently, a major health problem worldwide. It affects …

Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid
deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia …

Non-alcoholic fatty liver disease (NAFLD) is reaching epidemic proportions in patients with
type 2 diabetes. Patients with NAFLD are at increased risk of more aggressive liver disease …

Obesity, insulin resistance, and diabetes are strongly linked to the accumulation of
excessive lipids in the liver parenchyma, a condition known as nonalcoholic fatty liver …

The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide.
Globally, it is currently the most common liver disease and is estimated to affect up to 25% of …

Non-alcoholic fatty liver disease (NAFLD) is one the fastest emerging manifestations of the
metabolic syndrome worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form …

Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) refers to the accumulation of lipid laden
vacuoles in hepatocytes, occurring in the context of visceral adiposity, insulin resistance and …

Nonalcoholic fatty liver disease (NAFLD) is a well recognised form of chronic liver disease
that has recently gained greater recognition. Originally described in the late 1950s, NAFLD …

Non‐alcoholic fatty liver disease (NAFLD) is an umbrella term for a series of hepatic
pathologies that begin with relatively benign steatosis and can, with appropriate triggers …